We’re excited to announce that Biocytogen will be attending the 6th Ace Drug Discovery Summit in London. From synthetic biology and antibody engineering to structure-based drug development and advances in cell and gene therapy, the event will cover the trends shaping the future of drug discovery. Come meet our team at booth E5 to learn more about how Biocytogen is driving scientific excellence.
What is the 6th Ace Drug Discovery Summit?
The 6th Ace Drug Discovery Summit will explore new research, emerging technologies, and real-world applications that bridge academia, industry, and clinical practice. With over 120 attendees and 30 speakers, the event offers a highly collaborative environment with many opportunities to network and exchange insights with key decision makers and industry experts.
Event Overview
Date: February 18th-19th, 2026
Venue: The Insurance Hall, 20-21 Aldermanbury, London EC2V 7HY, UK
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in London!
